These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9548451)

  • 1. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma.
    Suzuki A; Toi M; Yamamoto Y; Saji S; Muta M; Tominaga T
    Jpn J Cancer Res; 1998 Feb; 89(2):221-7. PubMed ID: 9548451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein.
    Gudas JM; Nguyen H; Li T; Sadzewicz L; Robey R; Wosikowski K; Cowan KH
    Carcinogenesis; 1996 Jul; 17(7):1417-27. PubMed ID: 8706243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1.
    Giannikaki E; Kouvidou C; Tzardi M; Stefanaki K; Koutsoubi K; Gregoriou M; Zois E; Kakolyris S; Mavroudi C; Delides G; Georgoulias V; Kanavaros P
    Anticancer Res; 1997; 17(3C):2123-7. PubMed ID: 9216675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
    Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells.
    Zhou M; Gu L; Findley HW; Jiang R; Woods WG
    Cancer Res; 2003 Oct; 63(19):6357-62. PubMed ID: 14559824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
    Wang H; Nan L; Yu D; Agrawal S; Zhang R
    Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on p53, mdm-2 and p21WAF1 protein expression in ER-positive and ER-negative human breast cancer cell lines and its relation to biological features].
    Jiang M; Shao Z; Zhang Y
    Zhonghua Bing Li Xue Za Zhi; 1997 Dec; 26(6):327-30. PubMed ID: 10374318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
    Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
    Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of p21waf1/Cip1, MDM2 and p53 in vivo: analysis of cytological preparations.
    Dowell SP; McGoogan E; Picksley SM; el-Deiry WS; Vogelstein B; Hall PA
    Cytopathology; 1996 Oct; 7(5):340-51. PubMed ID: 8911758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target.
    Picksley SM; Spicer JF; Barnes DM; Lane DP
    Acta Oncol; 1996; 35(4):429-34. PubMed ID: 8695156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
    Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
    Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
    Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
    Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53-independent down-regulation of Mdm2 in human cancer cells treated with adriamycin.
    Ma Y; Yuan R; Meng Q; Goldberg ID; Rosen EM; Fan S
    Mol Cell Biol Res Commun; 2000 Feb; 3(2):122-8. PubMed ID: 10775510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
    Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
    Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of simultaneous expression of p21 and mdm2 in breast carcinomas treated by adjuvant chemotherapy with antracyclin.
    Mathoulin-Portier MP; Viens P; Cowen D; Bertucci F; Houvenaeghel G; Geneix J; Puig B; Bardou VJ; Jacquemier J
    Oncol Rep; 2000; 7(3):675-80. PubMed ID: 10767389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of MDM2 in MCF-7 promotes both growth advantage and p53 accumulation in response to estradiol.
    Saji S; Nakashima S; Hayashi S; Toi M; Saji S; Nozawa Y
    Jpn J Cancer Res; 1999 Feb; 90(2):210-8. PubMed ID: 10189892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The high levels of p53 present in adenovirus early region 1-transformed human cells do not cause up-regulation of MDM2 expression.
    Grand RJ; Lecane PS; Owen D; Grant ML; Roberts S; Levine AJ; Gallimore PH
    Virology; 1995 Jul; 210(2):323-34. PubMed ID: 7618270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
    Swaroop M; Sun Y
    Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
    Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The consequence of p53 overexpression for liver tumor development and the response of transformed murine hepatocytes to genotoxic agents.
    Gillet R; Grimber G; Bennoun M; Caron de Fromentel C; Briand P; Joulin V
    Oncogene; 2000 Jul; 19(31):3498-507. PubMed ID: 10918608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.